EUVIMEDEUVIMED entdecken
Open Access

Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Doris K Hansen iD, Surbhi Sidana iD, Lauren C Peres iD, Christelle Colin Leitzinger iD, Leyla Shune, Alexandria Shrewsbury, Rebecca Gonzalez iD, Douglas W Sborov iD, Charlotte Wagner iD, Danai Dima iD, Hamza Hashmi, Mehmet H Kocoglu iD und 13 weitere

Journal of Clinical Oncology · 10.04.2023 · 41 (11) · 2087-2097

DOI: 10.1200/jco.22.01365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2023. Verfasst von Doris K Hansen und 24 weiteren Autor:innen. Beteiligte Einrichtung: H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Hauptthemen laut MEDLINE: Multiple Myeloma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 291-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen–directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of the phase II pivotal KarMMa trial, which demonstrated best overall and ≥ complete response rates of 73% and 33%, respectively. We report clinical outcomes with standard-of-care (SOC) ide-cel under the commercial Food and Drug Administration label. METHODS Data were retrospectively collected from patients with RRMM who underwent leukapheresis as of February 28, 2022, at 11 US institutions with intent to receive SOC ide-cel. Toxicities were graded per American Society for Transplantation and Cellular Therapy guidelines and managed according to each institution's policies. Responses were graded on the basis of the International Myeloma Working Group response criteria. RESULTS One hundred fifty-nine of 196 leukapheresed patients received ide-cel by data cutoff. One hundred twenty (75%) infused patients would have been ineligible for participation in the KarMMa clinical trial because of comorbidities at the time of leukapheresis. Any grade and grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 82/3% and 18/6%, respectively. Best overall and ≥ complete response rates were 84% and 42%, respectively. At a median follow-up of 6.1 months from chimeric antigen receptor T infusion, the median progression-free survival was 8.5 months (95% CI, 6.5 to not reached) and the median overall survival was 12.5 months (95% CI, 11.3 to not reached). Patients with previous exposure to B-cell maturation antigen–targeted therapy, high-risk cytogenetics, Eastern Cooperative Oncology Group performance status ≥ 2 at lymphodepletion, and younger age had inferior progression-free survival on multivariable analysis. CONCLUSION The safety and efficacy of ide-cel in patients with RRMM in the SOC setting were comparable with those in the phase II pivotal KarMMa trial despite most patients (75%) not meeting trial eligibility criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaReceptors, Chimeric AntigenHumansB-Cell Maturation AntigenRetrospective StudiesImmunotherapy, AdoptiveCytokine Release Syndrome

Substanzen

idecabtagene vicleucelReceptors, Chimeric AntigenB-Cell Maturation Antigen

Autor:innen und Institutionen

  • H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
  • Stanford University School of Medicine, Stanford, CA.
  • The University of Kansas Medical Center, Kansas City, KS.
  • The University of Utah Huntsman Cancer Institute, Salt Lake City, UT.
  • Cleveland Clinic Taussig Cancer Center, Cleveland, OH.
  • Medical University of South Carolina, Charleston, SC.

ORCID-Profile: Doris K Hansen, Surbhi Sidana, Lauren C Peres, Christelle Colin Leitzinger, Rebecca Gonzalez, Douglas W Sborov, Charlotte Wagner, Danai Dima, Mehmet H Kocoglu, Shebli Atrash, Aimaz Afrough, Ankit Kansagra, Peter Voorhees, Rachid Baz, Jack Khouri, Joseph McGuirk, Frederick L Locke

Zitieren

APA

Hansen, D. K., Sidana, S., Peres, L. C., Colin Leitzinger, C., Shune, L., Shrewsbury, A., Gonzalez, R., Sborov, D. W., Wagner, C., Dima, D., Hashmi, H., Kocoglu, M. H., Atrash, S., Simmons, G., Kalariya, N., Ferreri, C., Afrough, A., Kansagra, A., Voorhees, P., …, & Patel, K. K. (2023). Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. Journal of Clinical Oncology, 41(11), 2087-2097. https://doi.org/10.1200/jco.22.01365

Vancouver

Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. Journal of Clinical Oncology. 2023;41(11):2087-2097. doi:10.1200/jco.22.01365

BibTeX
@article{Hansen2023,
  author = {Hansen, Doris K and Sidana, Surbhi and Peres, Lauren C and Colin Leitzinger, Christelle and Shune, Leyla and Shrewsbury, Alexandria and Gonzalez, Rebecca and Sborov, Douglas W and Wagner, Charlotte and Dima, Danai and Hashmi, Hamza and Kocoglu, Mehmet H and Atrash, Shebli and Simmons, Gary and Kalariya, Nilesh and Ferreri, Christopher and Afrough, Aimaz and Kansagra, Ankit and Voorhees, Peter and Baz, Rachid and Khouri, Jack and Alsina, Melissa and McGuirk, Joseph and Locke, Frederick L and Patel, Krina K},
  title = {Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {11},
  pages = {2087--2097},
  doi = {10.1200/jco.22.01365}
}
Kostenlos starten →